Amy Vandekop
Fortuna: 3 830 $ al 31/08/2026
Fortuna: 3 830 $ al 31/08/2026
Ms. Amy Vandekop, CPA, is a Chief Accounting Officer & Controller at Kalaris Therapeutics, Inc. Ms. Vandekop was previously employed as a Senior Director-Accounting & Reporting by AlloVir, Inc. and a Senior Manager-Accounting & Reporting by Lumicell, Inc. She received her undergraduate degree from the University of Massachusetts Amherst.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
0 % | 27/08/2026 | 948 ( 0 % ) | 3 830 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|
| Empresas | Cargo | Fin |
|---|---|---|
| ALLOVIRPAR | Comptroller/Controller/Auditor | 01/03/2025 |
Lumicell, Inc.
Lumicell, Inc. Electronic Equipment/InstrumentsElectronic Technology Develops and markets image-guided cancer surgery solutions | Comptroller/Controller/Auditor | 01/12/2020 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Lumicell, Inc.
Lumicell, Inc. Electronic Equipment/InstrumentsElectronic Technology Develops and markets image-guided cancer surgery solutions | Electronic Technology |
AlloVir, Inc.
AlloVir, Inc. BiotechnologyHealth Technology Develops cellular immunotherapies for severe infections | Health Technology |
University of Massachusetts Amherst
University of Massachusetts Amherst Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.